Bausch health's bausch + lomb to acquire novartis' xiidra(r)

Laval, qc / accesswire / june 30, 2023 / bausch + lomb corporation (nyse/tsx:blco), a subsidiary of bausch health companies inc. (nyse/tsx:bhc), announced that it has entered into a definitive agreement with novartis to acquire xiidra® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (ded) focusing on inflammation associated with dry eye. under the terms of the agreement, bausch + lomb, through an affiliate, has agreed to acquire xiidra, libvatrep and acustream from novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.
BLCO Ratings Summary
BLCO Quant Ranking